SCHEMBL4664692

SCHEMBL4664692

CC(=O)N(C)c1cc2c(nc(C)n2C)c(O)c1CN(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.33
MAPT P10636 4/20 0.33
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 1/20 0.33
RXFP1 Q9HBX9 1/20 0.32
ERAP1 Q9NZ08 1/20 0.32
PKM P14618 1/20 0.32
MLNR O43193 1/20 0.32
NR1I2 O75469 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
ADORA2A P29274 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663216 0.80 DHFR (0.35) GAAMAPTALDH1A1KMT2ASMN1; SMN2
SCHEMBL4574787 0.79 MEN1 (0.33) GAAMAPTALDH1A1MEN1KMT2A
SCHEMBL5116642 0.76 GAA (0.43) GAAMAPTALDH1A1MEN1KMT2A
SCHEMBL4664846 0.71 ALDH1A1 (0.33) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL16660490 0.68 ADRB2 (0.51) GAAMAPTALDH1A1MEN1KMT2A
SCHEMBL4737338 0.68 KDM4E (0.36) GAAALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4666506 0.65 MAP4K1 (0.33) GAAMAPTALDH1A1MEN1KMT2A
SCHEMBL13983543 0.63 CYP3A4 (0.60) KMT2AKCNH2SMN1; SMN2NPC1RAB9A
SCHEMBL4963781 0.62 CTNNB1 (0.35) GAAALDH1A1MEN1KMT2ACHRM2
SCHEMBL4664627 0.61 KMT2A (0.42) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113963-A1 Cyclic benzimidazoles ALTANA PHARMA AG (DE) 2008-05-15 US disclosed
US-7307084-B2 Cyclic benzimidazoles ALTANA PHARMA AG (DE) 2007-12-11 US disclosed
US-20060194968-A1 Cyclic benizimidazoles ALTANA PHARMA AG (DE) 2006-08-31 US disclosed
EP-1613626-A1 CYCLIC BENZIMIDAZOLES ALTANA Pharma AG (DE) 2006-01-11 EP disclosed
WO-2004087701-A1 CYCLIC BENZIMIDAZOLES ALTANA PHARMA AG (DE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194968-A1 Cyclic benizimidazoles VIP, SI, GIPR GAA 418/4885MAPT 4780/4885ALDH1A1 293/4885
US-20080113963-A1 Cyclic benzimidazoles VIP, GIPR, SI GAA 65/4885MAPT 4866/4885ALDH1A1 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.